Literature DB >> 22106226

Influence of body weight, ethnicity, oral contraceptives, and pregnancy on the pharmacokinetics of azithromycin in women of childbearing age.

James H Fischer1, Gloria E Sarto, Mitra Habibi, Sarah J Kilpatrick, Ruth E Tuomala, Janice M Shier, Lori Wollett, Patricia A Fischer, Kinnari S Khorana, Keith A Rodvold.   

Abstract

Women of childbearing age commonly receive azithromycin for the treatment of community-acquired infections, including during pregnancy. This study determined azithromycin pharmacokinetics in pregnant and nonpregnant women and identified covariates contributing to pharmacokinetic variability. Plasma samples were collected by using a sparse-sampling strategy from pregnant women at a gestational age of 12 to 40 weeks and from nonpregnant women of childbearing age receiving oral azithromycin for the treatment of an infection. Pharmacokinetic data from extensive sampling conducted on 12 healthy women were also included. Plasma samples were assayed for azithromycin by high-performance liquid chromatography. Population data were analyzed by nonlinear mixed-effects modeling. The population analysis included 53 pregnant and 25 nonpregnant women. A three-compartment model with first-order absorption and a lag time provided the best fit of the data. Lean body weight, pregnancy, ethnicity, and the coadministration of oral contraceptives were covariates identified as significantly influencing the oral clearance of azithromycin and, except for oral contraceptive use, intercompartmental clearance between the central and second peripheral compartments. No other covariate relationships were identified. Compared to nonpregnant women not receiving oral contraceptives, a 21% to 42% higher dose-adjusted azithromycin area under the plasma concentration-time curve (AUC) occurred in non-African American women who were pregnant or receiving oral contraceptives. Conversely, azithromycin AUCs were similar between pregnant African American women and nonpregnant women not receiving oral contraceptives. Although higher levels of maternal and fetal azithromycin exposure suggest that lower doses be administered to non-African American women during pregnancy, the consideration of azithromycin pharmacodynamics during pregnancy should guide any dose adjustments.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22106226      PMCID: PMC3264225          DOI: 10.1128/AAC.00717-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  52 in total

1.  A formula to estimate the approximate surface area if height and weight be known. 1916.

Authors:  D Du Bois; E F Du Bois
Journal:  Nutrition       Date:  1989 Sep-Oct       Impact factor: 4.008

Review 2.  On some "disadvantages" of the population approach.

Authors:  Jerry R Nedelman
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

3.  Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects.

Authors:  G W Amsden; A N Nafziger; G Foulds
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

4.  Some considerations on the design of population pharmacokinetic studies.

Authors:  Stephen Duffull; Tim Waterhouse; John Eccleston
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

5.  A study of the pharmacokinetics of azithromycin and nelfinavir when coadministered in healthy volunteers.

Authors:  G W Amsden; A N Nafziger; G Foulds; L J Cabelus
Journal:  J Clin Pharmacol       Date:  2000-12       Impact factor: 3.126

6.  Comparative studies of azithromycin in skin and soft-tissue infections and sexually transmitted infections by Neisseria and Chlamydia species.

Authors:  A Lassus
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

7.  Efficacy and safety of azithromycin 1 g once daily for 3 days in the treatment of community-acquired pneumonia: an open-label randomised comparison with amoxicillin-clavulanate 875/125 mg twice daily for 7 days.

Authors:  R Paris; M Confalonieri; R Dal Negro; G P Ligia; L Mos; T Todisco; V Rastelli; G Perna; M Cepparulo
Journal:  J Chemother       Date:  2008-02       Impact factor: 1.714

8.  Antibiotics potentially used in response to bioterrorism and the risk of major congenital malformations.

Authors:  William O Cooper; Sonia Hernandez-Diaz; Patrick G Arbogast; Judith A Dudley; Shannon M Dyer; Patricia S Gideon; Kathleen S Hall; Lisa A Kaltenbach; Wayne A Ray
Journal:  Paediatr Perinat Epidemiol       Date:  2009-01       Impact factor: 3.980

9.  Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats.

Authors:  Emiko Asakura; Hironao Nakayama; Masami Sugie; Ying Lan Zhao; Masayuki Nadai; Kiyoyuki Kitaichi; Akemi Shimizu; Mika Miyoshi; Kenji Takagi; Kenzo Takagi; Takaaki Hasegawa
Journal:  Eur J Pharmacol       Date:  2004-01-26       Impact factor: 4.432

Review 10.  Clarithromycin and azithromycin: new macrolide antibiotics.

Authors:  S C Piscitelli; L H Danziger; K A Rodvold
Journal:  Clin Pharm       Date:  1992-02
View more
  9 in total

1.  Sarah J. Kilpatrick, MD, PhD, Editor for AJOG.

Authors:  Roberto Romero
Journal:  Am J Obstet Gynecol       Date:  2019-05       Impact factor: 8.661

2.  Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy.

Authors:  James H Fischer; Gloria E Sarto; Jennifer Hardman; Loraine Endres; Thomas M Jenkins; Sarah J Kilpatrick; Hyunyoung Jeong; Stacie Geller; Kelly Deyo; Patricia A Fischer; Keith A Rodvold
Journal:  Clin Pharmacokinet       Date:  2014-04       Impact factor: 6.447

3.  Population Pharmacokinetics of Rifampin in Pregnant Women with Tuberculosis and HIV Coinfection in Soweto, South Africa.

Authors:  Paolo Denti; Neil Martinson; Silvia Cohn; Fildah Mashabela; Jennifer Hoffmann; Reginah Msandiwa; Sandra Castel; Lubbe Wiesner; Richard E Chaisson; Helen McIlleron; Kelly E Dooley
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

Review 4.  Basic obstetric pharmacology.

Authors:  Yang Zhao; Mary F Hebert; Raman Venkataramanan
Journal:  Semin Perinatol       Date:  2014-10-01       Impact factor: 3.300

5.  Maternal intravenous administration of azithromycin results in significant fetal uptake in a sheep model of second trimester pregnancy.

Authors:  Matthew W Kemp; Yuichiro Miura; Matthew S Payne; Alan H Jobe; Suhas G Kallapur; Masatoshi Saito; Sarah J Stock; O Brad Spiller; Demelza J Ireland; Nobuo Yaegashi; Michael Clarke; Dorothee Hahne; Jennifer Rodger; Jeffrey A Keelan; John P Newnham
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

6.  Pregnancy outcome in relation to treatment of murine typhus and scrub typhus infection: a fever cohort and a case series analysis.

Authors:  Rose McGready; John Antony Jude Prakash; Santosh Joseph Benjamin; Wanitda Watthanaworawit; Tippawan Anantatat; Ampai Tanganuchitcharnchai; Clare L Ling; Saw Oo Tan; Elizabeth A Ashley; Mupawjay Pimanpanarak; Stuart D Blacksell; Nicholas P Day; Pratap Singhasivanon; Nicholas J White; François Nosten; Daniel H Paris
Journal:  PLoS Negl Trop Dis       Date:  2014-11-20

Review 7.  Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review.

Authors:  Gali Pariente; Tom Leibson; Alexandra Carls; Thomasin Adams-Webber; Shinya Ito; Gideon Koren
Journal:  PLoS Med       Date:  2016-11-01       Impact factor: 11.069

Review 8.  Obstetric Pharmacokinetic Dosing Studies are Urgently Needed.

Authors:  Shelley A McCormack; Brookie M Best
Journal:  Front Pediatr       Date:  2014-02-11       Impact factor: 3.418

Review 9.  Drug Dosing in Pregnant Women: Challenges and Opportunities in Using Physiologically Based Pharmacokinetic Modeling and Simulations.

Authors:  Alice Ban Ke; Rick Greupink; Khaled Abduljalil
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-01-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.